Antibody administration following saline or BTX administration at the beginning of the treatment. Anti-IGF1R antibody treatment is denoted as IGF1R and control IgG antibody treatment as control IgG.

Botulinum toxin therapy has emerged as a pivotal treatment in the management of spasticity, a debilitating neuromuscular condition characterised by increased muscle tone and hyperactive reflexes. By ...

PHOENIX -- Botulinum toxin injections offered relief from sialorrhea, or excessive saliva production, in patients with amyotrophic lateral sclerosis (ALS), according to a small study. The ...

PHILADELPHIA, PA - Elan Pharmaceuticals announced today that it is investigating the potential use of MYOBLOC-3/8 (Botulinum Toxin Type B) Injectable Solution in a variety of spasticity, pain and ...

The use of toxin botulinum-A is one of the most rapidly growing areas in cosmetic dermatology. There is always news about this incredible substance. There are new indications, new techniques, and new ...

Please provide your email address to receive an email when new articles are posted on . Botulinum toxin A significantly improved tear breakup time, tear meniscus height and Schirmer test score.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

A new study published in the journal of The Laryngoscope showed that both in-office and operating room botulinum toxin ...

Botulinum toxin is the most common non-surgical procedure performed globally, with nearly nine million procedures estimated to take place each year. In the UK alone, around 900,000 botulinum toxin ...

Gigagen Inc., a subsidiary of Grifols SA, has been awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a recombinant polyclonal antibody therapy ...